EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ZYME, ANAB, QURE, JAZZ, CRNX, and represent 60.94% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: ORIC (+$61M), Bridgebio Oncology Therapeut (+$33M), GLPG (+$22M), MBX (+$17M), AQST (+$15M), CNTA (+$13M), RNA (+$12M), PRME (+$8.6M), PEPG, CMPS.
- Started 6 new stock positions in PRME, PEPG, AQST, Bridgebio Oncology Therapeut, CNTA, CMPS.
- Reduced shares in these 10 stocks: APLS (-$191M), Iteos Therapeutics (-$107M), JANX (-$34M), KURA (-$29M), AKRO (-$24M), VRNA (-$19M), TECX (-$19M), VYGR (-$15M), PCRX (-$11M), REPL (-$7.9M).
- Sold out of its positions in WHWK, ADAP, AKRO, DAWN, Hillevax, Iteos Therapeutics, JANX, MGNX, PCRX, REPL. TECX, VRNA.
- EcoR1 Capital was a net seller of stock by $-299M.
- EcoR1 Capital has $2.1B in assets under management (AUM), dropping by 23.35%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 30 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Zymeworks Del (ZYME) | 18.8 | $392M | 23M | 17.08 |
|
|
| Anaptysbio Inc Common (ANAB) | 11.6 | $241M | 7.9M | 30.62 |
|
|
| Uniqure Nv SHS (QURE) | 11.2 | $233M | -3% | 4.0M | 58.37 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 10.8 | $225M | 1.7M | 131.80 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 8.6 | $179M | 4.3M | 41.65 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 4.3 | $90M | 1.4M | 64.81 |
|
|
| Tango Therapeutics (TNGX) | 4.3 | $89M | 11M | 8.40 |
|
|
| Oric Pharmaceuticals (ORIC) | 3.9 | $81M | +315% | 6.7M | 12.00 |
|
| Apellis Pharmaceuticals (APLS) | 3.7 | $78M | -71% | 3.4M | 22.63 |
|
| Xencor (XNCR) | 3.5 | $72M | 6.1M | 11.73 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 2.8 | $58M | +60% | 1.7M | 34.64 |
|
| Immunome (IMNM) | 2.3 | $48M | 4.1M | 11.71 |
|
|
| Eton Pharmaceuticals (ETON) | 2.1 | $44M | 2.0M | 21.73 |
|
|
| Mbx Biosciences (MBX) | 1.8 | $37M | +84% | 2.1M | 17.50 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.7 | $34M | 75k | 458.66 |
|
|
| Avidity Biosciences Ord (RNA) | 1.6 | $33M | +53% | 765k | 43.57 |
|
| Bridgebio Oncology Therapeut Com New Added | 1.6 | $33M | NEW | 2.8M | 11.58 |
|
| Neurogene (NGNE) | 1.1 | $22M | 1.3M | 17.33 |
|
|
| Alkermes SHS (ALKS) | 0.7 | $15M | 500k | 30.00 |
|
|
| Aquestive Therapeutics (AQST) | 0.7 | $15M | NEW | 2.6M | 5.59 |
|
| Mestera (MTSR) | 0.7 | $14M | 272k | 52.33 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.6 | $13M | NEW | 550k | 24.25 |
|
| Prime Medicine (PRME) | 0.4 | $8.6M | NEW | 1.5M | 5.54 |
|
| Atara Biotherapeutics Com New (ATRA) | 0.4 | $8.2M | 573k | 14.33 |
|
|
| Kura Oncology (KURA) | 0.4 | $7.7M | -79% | 873k | 8.85 |
|
| Pepgen (PEPG) | 0.2 | $3.7M | NEW | 800k | 4.62 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.2 | $3.6M | 963k | 3.70 |
|
|
| Voyager Therapeutics (VYGR) | 0.2 | $3.1M | -82% | 670k | 4.67 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $1.5M | NEW | 265k | 5.73 |
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $859k | 67k | 12.89 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2025 Q3 filed Nov. 14, 2025
- EcoR1 Capital 2025 Q2 filed Aug. 14, 2025
- EcoR1 Capital 2025 Q1 filed May 15, 2025
- EcoR1 Capital 2024 Q4 filed Feb. 14, 2025
- EcoR1 Capital 2024 Q3 filed Nov. 14, 2024
- EcoR1 Capital 2024 Q2 filed Aug. 14, 2024
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022